Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination
The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2021.752233/full |
| _version_ | 1819130207933562880 |
|---|---|
| author | Hamad Ali Hamad Ali Abdulmohsen Alterki Abdulmohsen Alterki Sardar Sindhu Sardar Sindhu Barrak Alahmad Maha Hammad Salman Al-Sabah Mohammad Alghounaim Mohammad H. Jamal Ali Aldei Mohammad J. Mairza Maitham Husain Sriraman Deverajan Rasheed Ahmad Preethi Cherian Irina Alkhairi Abdullah Alkandari Jehad Abubaker Mohamed Abu-Farha Fahd Al-Mulla |
| author_facet | Hamad Ali Hamad Ali Abdulmohsen Alterki Abdulmohsen Alterki Sardar Sindhu Sardar Sindhu Barrak Alahmad Maha Hammad Salman Al-Sabah Mohammad Alghounaim Mohammad H. Jamal Ali Aldei Mohammad J. Mairza Maitham Husain Sriraman Deverajan Rasheed Ahmad Preethi Cherian Irina Alkhairi Abdullah Alkandari Jehad Abubaker Mohamed Abu-Farha Fahd Al-Mulla |
| author_sort | Hamad Ali |
| collection | DOAJ |
| description | The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people (81 diabetic and 181 non-diabetic persons) that took two doses of BNT162b2 (Pfizer–BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. The mean ( ± 1 standard deviation) levels were 154 ± 49.1 vs. 138 ± 59.4 BAU/ml for IgG and 87.1 ± 11.6 vs. 79.7 ± 19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection, and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95% CI: 27.08 to 0.64 BAU/ml, p=0.041) less IgG antibodies and 4.42% (95% CI: 8.53 to 0.32%, p=0.036) fewer neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity. Nonetheless, it is important that people get their COVID-19 vaccination especially people with diabetes. |
| first_indexed | 2024-12-22T08:55:57Z |
| format | Article |
| id | doaj.art-1e20e1ab130b4508b7d668fccca55432 |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-12-22T08:55:57Z |
| publishDate | 2021-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-1e20e1ab130b4508b7d668fccca554322022-12-21T18:31:50ZengFrontiers Media S.A.Frontiers in Immunology1664-32242021-11-011210.3389/fimmu.2021.752233752233Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 VaccinationHamad Ali0Hamad Ali1Abdulmohsen Alterki2Abdulmohsen Alterki3Sardar Sindhu4Sardar Sindhu5Barrak Alahmad6Maha Hammad7Salman Al-Sabah8Mohammad Alghounaim9Mohammad H. Jamal10Ali Aldei11Mohammad J. Mairza12Maitham Husain13Sriraman Deverajan14Rasheed Ahmad15Preethi Cherian16Irina Alkhairi17Abdullah Alkandari18Jehad Abubaker19Mohamed Abu-Farha20Fahd Al-Mulla21Department of Medical Laboratory Sciences, Faculty of Allied Health Sciences, Health Sciences Center (HSC), Kuwait University, Jabriya, KuwaitDepartment of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Otolaryngology, Head, and Neck Surgery, Zain and Al-Sabah Hospitals, Ministry of Health, Kuwait City, KuwaitMedical Division, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Immunology and Microbiology, Dasman Diabetes Institute (DDI), Dasman, KuwaitAnimal & Imaging Core Facility, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Environmental Health, Harvard T.H. Chan School of Public Health, Harvard University, Boston, MA, United StatesDepartment of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman, KuwaitCOVID-19 Research Group, Jaber Al-Ahmad Al-Sabah Hospital, Kuwait City, KuwaitCOVID-19 Research Group, Jaber Al-Ahmad Al-Sabah Hospital, Kuwait City, KuwaitCOVID-19 Research Group, Jaber Al-Ahmad Al-Sabah Hospital, Kuwait City, Kuwait0Rheumatology Unit, Department of Medicine, Amiri Hospital, Kuwait City, Kuwait1Department of Internal Medicine, Amiri Hospital, Kuwait City, Kuwait2Planning and Follow-Up Department, Ministry of Health, Kuwait City, Kuwait3National Dasman Diabetes Biobank, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Immunology and Microbiology, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Biochemistry and Molecular Biology, Dasman Diabetes Institute (DDI), Dasman, KuwaitDepartment of Genetics and Bioinformatics, Dasman Diabetes Institute (DDI), Dasman, KuwaitThe emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based vaccine. We aimed to evaluate the levels of anti-SARS-CoV-2 IgG and neutralizing antibodies in people with T2DM and/or other metabolic risk factors (hypertension and obesity) compared to those without. This study included 262 people (81 diabetic and 181 non-diabetic persons) that took two doses of BNT162b2 (Pfizer–BioNTech) mRNA vaccine. Both T2DM and non-diabetic individuals had a robust response to vaccination as demonstrated by their high antibody titers. However, both SARS-CoV-2 IgG and neutralizing antibodies titers were lower in people with T2DM. The mean ( ± 1 standard deviation) levels were 154 ± 49.1 vs. 138 ± 59.4 BAU/ml for IgG and 87.1 ± 11.6 vs. 79.7 ± 19.5% for neutralizing antibodies in individuals without diabetes compared to those with T2DM, respectively. In a multiple linear regression adjusted for individual characteristics, comorbidities, previous COVID-19 infection, and duration since second vaccine dose, diabetics had 13.86 BAU/ml (95% CI: 27.08 to 0.64 BAU/ml, p=0.041) less IgG antibodies and 4.42% (95% CI: 8.53 to 0.32%, p=0.036) fewer neutralizing antibodies than non-diabetics. Hypertension and obesity did not show significant changes in antibody titers. Taken together, both type-2 diabetic and non-diabetic individuals elicited strong immune responses to SARS-CoV-2 BNT162b2 mRNA vaccine; nonetheless, lower levels were seen in people with diabetes. Continuous monitoring of the antibody levels might be a good indicator to guide personalized needs for further booster shots to maintain adaptive immunity. Nonetheless, it is important that people get their COVID-19 vaccination especially people with diabetes.https://www.frontiersin.org/articles/10.3389/fimmu.2021.752233/fullCOVID-19diabetes mellitus type 2vaccinemRNA vaccineBNT162b2T2D |
| spellingShingle | Hamad Ali Hamad Ali Abdulmohsen Alterki Abdulmohsen Alterki Sardar Sindhu Sardar Sindhu Barrak Alahmad Maha Hammad Salman Al-Sabah Mohammad Alghounaim Mohammad H. Jamal Ali Aldei Mohammad J. Mairza Maitham Husain Sriraman Deverajan Rasheed Ahmad Preethi Cherian Irina Alkhairi Abdullah Alkandari Jehad Abubaker Mohamed Abu-Farha Fahd Al-Mulla Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination Frontiers in Immunology COVID-19 diabetes mellitus type 2 vaccine mRNA vaccine BNT162b2 T2D |
| title | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
| title_full | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
| title_fullStr | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
| title_full_unstemmed | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
| title_short | Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination |
| title_sort | robust antibody levels in both diabetic and non diabetic individuals after bnt162b2 mrna covid 19 vaccination |
| topic | COVID-19 diabetes mellitus type 2 vaccine mRNA vaccine BNT162b2 T2D |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2021.752233/full |
| work_keys_str_mv | AT hamadali robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT hamadali robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT abdulmohsenalterki robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT abdulmohsenalterki robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT sardarsindhu robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT sardarsindhu robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT barrakalahmad robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT mahahammad robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT salmanalsabah robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT mohammadalghounaim robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT mohammadhjamal robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT alialdei robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT mohammadjmairza robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT maithamhusain robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT sriramandeverajan robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT rasheedahmad robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT preethicherian robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT irinaalkhairi robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT abdullahalkandari robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT jehadabubaker robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT mohamedabufarha robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination AT fahdalmulla robustantibodylevelsinbothdiabeticandnondiabeticindividualsafterbnt162b2mrnacovid19vaccination |